StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Jefferies: 'we can still see at least a +25-50% stock move if SRPT shows competitive/superior 6-month splicing/vHOT data'
September 8, 2026 1:25 PM
Jefferies analyst Andrew Tsai reiterated a Buy rating and $30.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst comments "Other ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
